Advertisement

Volume 129, Issue 9

Cover Figure: GVHD causes female infertility.
See the article by Shimoji et al.

WASHINGTON, March 2, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation
Ueda and colleagues demonstrate that a mutation in factor H disrupts host cell interactions, leading to dysregulation of complement, systemic thrombotic angiopathy, and hemolytic uremic syndrome.

Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
Kim et al investigate the preclinical therapeutic potential of targeting pre–B-cell receptor (pre-BCR) signaling in acute lymphoblastic leukemia (ALL). They postulate that ibrutinib offers a new therapeutic opportunity for pre-BCR–positive ALL.

Ask1 regulates murine platelet granule secretion, thromboxane A2 generation, and thrombus formation
Naik et al evaluate the link between platelet stimulation and mitogen-activated protein kinase (MAPK) activation and find a critical role for apoptosis signal-regulating kinase 1 (Ask1) in platelet function and thrombus formation.

Introduction to the review series on T-cell malignancies
This series of comprehensive reviews discusses the molecular pathobiology and molecular genetics of the highly diverse T-cell malignancies, outlines their diagnostic implications, and highlights novel therapeutic strategies.

The articles in this review series, "T-Cell Malignancies," include the following:

Graft-versus-host disease targets ovary and causes female infertility in mice
Shimoji et al demonstrate for the first time that female mice which develop acute graft-versus-host disease (GVHD) have reduced fertility and that donor CD8+ T lymphocytes are critical for the destruction of granulosa cells and the eventual loss of ovarian function. Furthermore, they show that GVHD prophylaxis preserves fertility.

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
In a comprehensive and provocative report, Hughes and colleagues report on the immune reconstitution that occurs as a consequence of the deepening remission achieved by patients with chronic myeloid leukemia (CML) who receive tyrosine kinase inhibitor (TKI) therapy.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Analysis of two consecutive randomized trials with newly diagnosed patients with mutant FLT3 acute myeloid leukemia (AML) suggests no benefit of the addition of the kinase inhibitor lestaurtinib to chemotherapy.

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.